Literature
Browse through a complete list of over 280 publications that have been published using DryLab®.
Showing 161–180 of 210 results for "reverse phase"
Unusual experiments can provide surprisingly good analytical solutions. When developing Chromatographic methods, analysts must use a combination of experience and instinct to choose initial starting conditions. This is often followed by a period of trial-and-error optimization until the desired methodology is achieved. This article illustrates how the process of Chromatographic method development can be improved using computer modelling and simulation.
Over a hundred acidic urinary constituents were separated within 30 min by using 5-μm octadecyl-silica columns and gradient elution with increasing acetonitrile concentration in dilute aqueous phosphoric acid solution at 70°. The column effluent was monitored with a UV detector at 280 nm or with a fluorescence detector at 260 nm excitation and 340 nm emission wavelengths. The high sensitivity and speed of analysis, the excellent reproducibility and adequate resolution obtained suggest that this technique may be useful to obtain metabolic profiles in routine clinical work.
The separation range of superficially porous particles (Fused-Core®) has been extended by design of particles with 160Å pores. These particles show superior kinetics (lower resistance to mass transfer), allowing fast separations of peptides and small proteins (molecular weights of <15,000). The high efficiency and relatively low back pressure of these 2.7μm Fused-Core particles has been maintained so that separations can be performed with conventional HPLC instruments. Longer columns can be used for higher resolution of complex mixtures of peptides, such as proteolytic digests. Highly reproducible separations of peptides at elevated temperatures with low pH mobile phases are maintained as a result of a stable bonded stationary phase. The utility of such highly stable materials is exemplified by separations of problematic amyloid peptides at low pH (TFA mobile phase) at an operational temperature of 100°C. To address the issue of poor peptide peak shape in formic acid-containing mobile phases we show that the addition of 10–20mM ammonium formate improves peak shape, retention and load tolerance of peptides. Use of the Fused-Core particle materials for separations of synthetic peptides and tryptic digests yields peak capacities that are comparable to those obtained using columns packed with sub-2-μm particles, but with less than one-half of the operating back pressure. A peak capacity of 530 was obtained in 150min on coupled columns of HALO Peptide ES-C18 with a combined length of 250mm.
In this study, a thin-layer chromatography (TLC) and a high performance liquid chromatographic (HPLC) methods were developed for the chemical profiling, qualitative and quantitative analysis of P. guineense extracts. To obtain a chromatogram with satisfactory resolution and favorable retention time, DryLab software was used to simulate and optimize a HPLC method for the analysis of P. guineense extracts. The aim was to achieve the best possible overall resolution while keeping the analysis time and solvent consumption to a minimum. With the optimized method, a total of 16 main components in the extract were separated with favorable resolution. Optimal TLC conditions were also developed using solvents of various solvent strength (ST) and solvent selectivity (PS) values. The mobile phase composition was systematically tested using various proportions of solvents differing in ST and PS values under the same experimental conditions. During the optimization, emphasis was set on achieving the best possible overall separation of the main components of the extracts (for example piperine). In addition, the effects of the developing chamber was tested using three types of unsaturated chamber conditions: horizontal chamber in sandwich configuration, horizontal chamber in non-sandwich configuration and twin-trough vertical chamber. During the study, a TLC method was developed, and the best mobile-phase composition giving favorable resolution of the bands was toluene: ethyl acetate (PS 6-4 corresponding to 60:40 % v/v). The developing chamber conditions did not affect the TLC separation efficacy in the analysis of P. guineense extracts. The HPLC method was applied to determine the percentage content of piperine in P. guineense. The piperine content was 0.43 % w/w, linearity (0.997), interday precision (% relative standard deviation (RSD), 1.6), intraday precision (% RSD, 2.7 – 5.9), recovery (98.4%), limit of detection (0.001 μg /mL) and limit of quantification (0.003 μg /mL).
In-silico optimisation of a two-dimensional high performance liquid chromatography (2D-HPLC) separation protocol has been developed for the interrogation of methamphetamine samples including model, real world seizure, and laboratory synthesised samples. The protocol used Drylab® software to rapidly identify the optimum separation conditions from a library of chromatography columns. The optimum separation space was provided by the Phenomonex Kinetex PFP column (first dimension) and an Agilent Poroshell 120 EC-C18 column (second dimension). To facilitate a rapid 2D-HPLC analysis the particle packed C18 column was replaced with a Phenomenex Onyx Monolithic C18 withought sacrificing separation performance. The Drylab® optimised and experimental separations matched very closely, highlighting the robust nature of HPLC simulations. The chemical information gained from an intermediate methamphetamine sample was significant and complimented that generated from a pure seizure sample. The influence of the two-dimensional separation on the analytical figures of merit was also investigated. The limits of detection for key analytes in the second dimension determined for methamphetamine (4.59ÿ10⿿4M), pseudoephedrine (4.03ÿ10⿿4M), caffeine (5.16ÿ10⿿4M), aspirin (9.32ÿ10⿿4M), paracetamol (5.93ÿ10⿿4M) and procaine (2.02ÿ10⿿3M).
Equipment for high-performance liquid chromatographic (HPLC) gradient elution generally distorts the gradient selected by the operator, which in turn affects the retention of solutes separated by gradient elution. A theoretical analysis describes these gradient distortions as a function of equipment design and operating conditions. Comparisons of theory with experimental data show generally good agreement. As a result, it is now possible to select gradient conditions for minimal gradient distortion, or to correct for the effect of gradient distortion on solute retention. This will be shown in later papers to allow the use of gradient elution in new ways for more efficient method development and optimization of separation by HPLC.
A RP-HPLC method for the separation and determination of impurities of moxifloxacin, in its pharmaceutical forms as well as moxifloxacin degradation products, was developed with the aid of DryLab® software and chemometric (response surface) approach. The separation of four synthesis-related impurities was achieved on a Waters C18 XTerra column using a mobile phase of (water+triethylamine (2%, v/v)): acetonitrile=90:10 (v/v%); the pH of water phase being adjusted with phosphoric acid to 6.0. Flow rate of the mobile phase was 1.5ml/min and UV detection at 290nm was employed. The column was thermostated at 45°C. The resolution between the two least resolved impurity peaks was in average, Rs,min>1.5. Method validation parameters indicate linear dynamic range 0.2–2.0μg/ml with LOQ ca. 0.20μg/ml and LOD ca. 0.05μg/ml for all analytes. The method was applied for the impurities determination in drug tablets and infusion (Avelox®, Bayer AG) and for degradation products determination in a stability study of moxifloxacin. The impurity content in the tablets and infusion was quantified as 0.1% of total drug. Two degradation products were noted under hydrolytic conditions. The method can also be used for rapid and accurate quantification of moxifloxacin hydrochloride in its tablets during stability testing.
The goals in ultrahigh-pressure liquid chromatography (UHPLC) method development are to first find the best separation, second find the best column, and third find the most robust method in a multifactorial Design Space. Trial and error methods are not sufficient anymore and solid science based on Quality by Design (QbD) principles is required.
Baclofen exhibits insufficient CNS-availability when dosed systemically. Hence, prodrug candidates (methyl, ethyl, 1-propyl, 2-propyl and butyl 4-(tert-butoxycarbonyl amino)-3-(4-chlorophenyl) butanoate) were synthesized aiming at CNS-levels appropriate for the treatment of spastic disorders. The characterization of some biopharmaceutically highly relevant physicochemical properties (LogP and aqueous solubility) and the evaluation of biophase levels represent one important component of the project. The overall research aim was to generate an HPLC optimized method using DryLab®, a simulation software for the optimization of a RP-HPLC method, which was optimized using a simulation software (DryLab®), for the simultaneous determination of baclofen and ten synthesized prodrug candidates. The chromatographic resolution predicted and obtained via the simulation is Rs >1.5 for all baclofen derivatives, as well as, with parent baclofen. The method was used to assay the prodrugs and determine their purities, solubility and lipophilicity parameters. The designed analytical method also permits the tracking of the new prodrug candidates’ hydrolysis in vitro and in vivo. The determined physicochemical properties indicate for some of the compounds that they might be suitable for CNS-targeting which was exemplified by the detection of significant baclofen levels in rat brain tissues following an i.p. dose of ethyl carbamate (vs. ethyl ester, for which only traces of baclofen were detected).
A platform analytical quality by design approach for methods development is presented in this paper. This approach is not limited just to method development following the same logical Analytical quality by design (AQbD) process, it is also exploited across a range of applications in methods development with commonality in equipment and procedures. As demonstrated by the development process of 3 methods, the systematic approach strategy offers a thorough understanding of the method scientific strength. The knowledge gained from the UHPLC-UV peptide mapping method can be easily transferred to the UHPLC–MS oxidation method and the UHPLC-UV C-terminal heterogeneity methods of the same protein. In addition, the platform AQbD method development strategy ensures method robustness is built in during development. In early phases, a good method can generate reliable data for product development allowing confident decision making. Methods generated following the AQbD approach have great potential for avoiding extensive post-approval analytical method change. While in the commercial phase, high quality data ensures timely data release, reduced regulatory risk, and lowered lab operational cost. Moreover, large, reliable database and knowledge gained during AQbD method development provide strong justifications during regulatory filling for the selection of important parameters or parameter change needs for method validation, and help to justify for removal of unnecessary tests used for product specifications.
The goal of this second part was (i) to evaluate the performance of commercially available HIC columns and (ii) to develop a fast and automated “phase system” (i.e. stationary phase and salt type) optimization procedure for the analytical characterization of protein biopharmaceuticals. For this purpose, various therapeutic mAbs (denosumab, palivizumab, pertuzumab, rituximab and bevacizumab) and a cysteine linked ADC (brentuximab-vedotin) were selected as model substances. Several HIC column chemistries (butyl, ether and alkylamide) from different providers were evaluated in four different buffer systems (sodium acetate, sodium chloride, ammonium acetate and ammonium sulfate). As stationary phases, the historical TSK gel Butyl NPR phase and the brand new Thermo MAbPac HIC-10 were found to be the most versatile ones in terms of hydrophobicity, peak capacity and achievable selectivity. As salt types, ammonium sulfate and sodium acetate were found to be particularly well adapted for the analytical characterization of mAbs and ADCs, but it is important to keep in mind that a concentration 2 to 3-times higher of sodium acetate versus ammonium sulfate is required to achieve a similar retention in HIC. After selection of the most appropriate phase systems, the optimization of the separation can be carried out by computer assisted retention modeling in a high throughput manner.
The process of developing a high-performance liquid chromatographic (HPLC) method for fractionating nitro derivatives of polyromatic hydrocarbons using the HPLC simulation program DryLab G is presented. A comparison of the computer-simulated results and experimental data revealed retention time prediction errors during preliminary stages of the method development. These errors resulted from the simulation of mobile phase conditions that required the program, based on the input data, to extrapolate beyond the point at which accurate retention times could be reasonably predicted. We discuss the cause and solution of these retention time prediction errors. After entering new input data, the final “optimum” HPLC method developed using Dry Lab G simulations correlated well with the experimentally observed chromatogram.
Quality-by-design (QbD) is a systematic approach to drug development, which begins with predefined objectives, and uses science and risk management approaches to gain product and process understanding and ultimately process control. The concept of QbD can be extended to analytical methods. QbD mandates the definition of a goal for the method, and emphasizes thorough evaluation and scouting of alternative methods in a systematic way to obtain optimal method performance. Candidate methods are then carefully assessed in a structured manner for risks, and are challenged to determine if robustness and ruggedness criteria are satisfied. As a result of these studies, the method performance can be understood and improved if necessary, and a control strategy can be defined to manage risk and ensure the method performs as desired when validated and deployed. In this review, the current state of analytical QbD in the industry is detailed with examples of the application of analytical QbD principles to a range of analytical methods, including high-performance liquid chromatography, Karl Fischer titration for moisture content, vibrational spectroscopy for chemical identification, quantitative color measurement, and trace analysis for genotoxic impurities.
A method for the assay of an active pharmaceutical ingredient (API) and five known and unknown impurities was developed in accordance with Quality by Design (QbD) principles. Highly influential separation parameters were simultaneously and systematically studied so that the quality of the HPLC method could be understood, controlled and ensured. Consequently, during routine analysis out of specification (OOS) results can be corrected more effectively.
In this era of competition quality has been given prime magnitude; failure to meet such quality allied goals produces massive shift of company in share of market. In this context pharmaceutical industry is utmost regulated industry as it is governed by authoritative regulatory bodies. “Quality could be planned and most of quality deficit arises in the way process is planned and developed”, this thought of well known quality expert Joseph Moses Juran gives foundation to the concept of quality by design (QbD). USFDA launched a pilot programme in 2005 to permit participating firms a prospect to submit chemistry, manufacturing, and controls (CMC) of NDA information representing application of QbD. Now USFDA is accelerating QbD drive by making warning to generic manufacturers from January 2013. QbD has its perspectives to contribute the drug design, development, and manufacture of high-quality drug products. In the present review basic consideration of the QbD approach, its historical background, and regulatory needs are discussed. In detail explanation of elements of QbD i.e. method intent, design of experiment, and risk assessment is given. Application of QbD to pharmaceutical and biopharmaceutical processes, development and unit operation associated with it are briefly mentioned. Detail account of QbD to analytical technique is explained thoroughly by referencing examples.
In high-performance liquid chromatography (HPLC), robust and easily transferable analytical methods are essential to ensure consistent performance throughout the entire lifecycle of an analytical procedure, including unforeseen future applications. Nevertheless, robustness-, and ruggedness-related issues are frequently reported in industrial practice, particularly during method transfer between laboratories. These challenges often arise from incomplete method understanding and insufficient consideration of HPLC system-related effects, such as dwell volume, extra-column contributions and other, at first less evident, instrument-to-instrument variations in solvent delivery, mixing behavior and column thermal control. In this context, modeling approaches aligned with Analytical Quality by Design (AQbD) principles provide valuable support for both proactive method development and reactive troubleshooting. In the current work, we used DryLab modeling Design Spaces (DSs) to create digitized modeling fingerprints of various instruments, enabling extensive in silico investigations, including in-depth assessment of method transferability and evaluation of subtle, instrument-dependent robustness characteristics.
Requirements for new pharmaceutical products and their impact on applications of high-performance liquid chromatography (HPLC) are discussed. The strengths and weaknesses of HPLC in this context are evaluated and compared with current trends and expectation in separation science.
Quality by design (QbD) is an approach to product development where a comprehensive understanding of the effect of various inputs (e.g. process parameters, materials) on the final product (active pharmaceutical ingredient or drug product), leads to a process or product design that ensures reliable manufacture of a high-quality product. Analogous to QbD for product, QbD may also be applied to analytical methods, by defining the required analytical performance and systematically relating how the technique and method parameters relate to analytical performance. Achieving the appropriate level of method understanding typically involves a multifactorial approach. The factors to be studied are identified via a systematic risk analysis, which allows truly impactful parameters to be further investigated in studies applying statistical design of experiments (DOE) or mechanistic models to develop a multidimensional region of experimental space in which the effects of key factors are understood and documented. An operating region can then be defined where there is high confidence that the method will operate reliably. Data generated during use of the method can be monitored over time to ensure continued adequate performance of the analysis.
The effect of solute ionization on the retention of weak acids, bases, and ampholytes on octadecylsilica was investigated both theoretically and experimentally. The retention was attributed to a reversible association of the solutes with the hydrocarbonaceous ligand of the stationary phase. A phenomenological treatment of the corresponding equilibria was developed for various types of ionogenic substances. The energetics of the association process was analyzed in a rigorous fashion in the light of the solvophobic theory and a semi-empirical extension of the Debye-Hiickel theory to high ionic strength. The predicted effect of solute ionization on the capacity factors was substantiated by experimental data. The observed dependence of the capacity factors on the ionic strength of the eluent and the hydrophobic surface of the solute molecules showed good agreement with the theory. The advantages of the technique in the separation of biological substances are illustrated.